Trial Profile
Phase I/II Study of Oral ONC201 in Patients With Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndromes
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Apr 2023
Price :
$35
*
At a glance
- Drugs Dordaviprone (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia; Leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- 29 Mar 2023 Planned End Date changed from 30 Nov 2023 to 30 Nov 2024.
- 29 Mar 2023 Planned primary completion date changed from 30 Nov 2022 to 30 Nov 2024.
- 10 Mar 2022 Planned number of patients changed from 150 to 120.